Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
|Videos|May 24, 2007
Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer
Author(s)David R. Gandara, MD
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Advertisement
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on HCPLive
1
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
2
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
Common Diuretic Linked to Home Blood Pressure Lowering After Stroke
5